Curia Unveils Comprehensive mRNA Solution

Curia, formerly AMRI, a leading contract research, development and manufacturing organization, today unveiled its messenger RNA (mRNA) solution, which includes discovery, process development and mRNA drug substance production, through large-scale lipid manufacturing, lipid nanoparticle (LNP) formulation and development for full-scale sterile fill-finish services.

Related Keywords

California ,United States ,Massachusetts ,John Ratliff ,Debra Harrsch ,Development Of Lipid Nanoparticle Formulation ,Development Of Lipid ,Media Communications ,Brandwidth Solutions ,Curia Chairman ,Chief Executive Officer John ,Substance Through ,Lipid Nanoparticle Formulation ,Sterile Fill Finish Through ,Media Contact ,Curia ,Emri ,Contract Research ,Development ,Messenger Rna ,Rna ,Discovery ,Process Development ,Lipid Nanoparticle ,Snp ,Ovid 19 Pandemic ,Molecular Biology ,Protein Production ,Enzymes ,Nucleosides ,Harmaceutical And Biopharmaceutical ,